Moderna: COVID-19 vaccine nets strong antibody response for kids age 6-11
Moderna today released topline results from its ongoing phase 2/3 clinical trial of its COVID-19 vaccine for children age 6 through 11, revealing a strong antibody response against SARS-CoV-2. Moderna is evaluating the safety, tolerability, reactogenicity and effectiveness of two 50-microgram doses of its mRNA-1273 vaccine administered 28 days apart. Moderna said its data, which has not been peer-reviewed, indicates antibodies levels that were up to 1.5 times as high as those generated in adults. The majority of adverse events were deemed mild or moderate in severity, most commonly manifesting as fatigue, headache, fever and injection-site pain.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…